Core Viewpoint - The company, along with its wholly-owned subsidiary Hunan Kangyuan Pharmaceutical Co., Ltd., is participating in the procurement bidding for drugs after the expiration of the national organized procurement agreement, with some products expected to be selected for this follow-up procurement [1] Group 1 - The projected sales revenue for the selected products in 2024 is 106 million yuan, accounting for 13.35% of the company's total revenue for that year [1] - For the first three quarters of 2025, the sales revenue is expected to be 66.0742 million yuan, representing 11.37% of the company's revenue during that period [1]